Skip to main content
SpringerLink
Log in

A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2V617F

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Historically, red cell mass (RCM) measurement has been promoted as an accurate indicator of the body’s red cell content. Both the Polycythemia Vera Study Group and a committee sponsored by the World Health Organization have endorsed its inclusion in their diagnostic criteria without supporting evidence of diagnostic accuracy from a systematic study. Over the years, it has become evident that RCM measurement is a cumbersome and costly test and, as a result, it has been abandoned by many hematologists in practice. The recent discovery that a somatic JAK2-activating mutation, JAK2V617F, is almost invariably associated with polycythemia vera further supports the use of diagnostic algorithms that are based on biologic parameters in place of traditional diagnostic criteria that are based on RCM measurement. Therefore, a contemporary approach to the diagnosis of polycythemia vera starts with peripheral blood mutation screening for JAK2V617F as well as measurement of serum erythropoietin. The results of these tests, along with the clinical scenario, determine the need for further investigation, including bone marrow examination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Adamson JW, Fialkow PJ, Murphy S, et al.: Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976, 295:913–916.

    Article  PubMed  CAS  Google Scholar 

  2. Finazzi G, Caruso V, Marchioli R, et al.: Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study. Blood 2005, 105:2664–2670. A very important source of information concerning hydroxyurea, regarding the lack of evidence for drug leukemogenicity.

    Article  PubMed  CAS  Google Scholar 

  3. Tefferi A, Gilliland DG: The JAK2 V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 2005, 80:947–958.

    PubMed  CAS  Google Scholar 

  4. Jones AV, Kreil S, Zoi K, et al.: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106:2162–2168. One of the first studies to reveal the occurrence of the JAK2V617F mutation in a diverse group of chronic myeloid disorders.

    Article  PubMed  CAS  Google Scholar 

  5. James C, Ugo V, Le Couedic JP, et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144–1148. A major discovery in polycythemia vera and related disorders.

    Article  PubMed  CAS  Google Scholar 

  6. Tefferi A, Sirhan S, Lasho TL, et al.: Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 2005, 131:166–171. The first study to systematically examine the practical value of mutation screening for JAK2V617F during the evaluation of polycythemia.

    Article  PubMed  CAS  Google Scholar 

  7. KralovicsR, Teo SS, Buser AS, et al.: Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005, 106:3374–3376. A very important laboratory study that supports the substitution of mutation screening for JAK2V617F for other specialized tests in the work-up of patients with suspected polycythemia vera.

    Article  PubMed  CAS  Google Scholar 

  8. Tefferi A, Spivak JL: Polycythemia vera: scientific advances and current practice. Semin Hematol 2005, 42:206–220.

    Article  PubMed  CAS  Google Scholar 

  9. Wasserman LR: The management of polycythemia vera. Br J Haematol 1971, 21:371–376.

    PubMed  CAS  Google Scholar 

  10. Vardiman JW, Brunning RD, Harris NL: WHO histological classification of chronic myeloproliferative diseases. In World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Edited by Jaffe ES, Harris NL, Stein H, Vardiman JW. Lyon, France: International Agency for Research on Cancer (IARC) Press; 2001:17–44.

    Google Scholar 

  11. Tefferi A: Polycythemia vera: a comprehensive review and clinical recommendations [review]. Mayo Clin Proc 2003, 78:174–194.

    PubMed  Google Scholar 

  12. National Center for Health Statistics: Mean blood hematocrit of adults: United States, 1960–1962. Washington, DC: Public Health Service Publication No. 1000, Series 11, No 24, 1967.

  13. Pearson TC: Apparent polycythaemia [review]. Blood Rev 1991, 5:205–213.

    Article  PubMed  CAS  Google Scholar 

  14. Fairbanks VF, Tefferi A: Normal ranges for packed cell volume and hemoglobin concentration in adults: relevance to ’apparent polycythemia’ [review]. Eur J Haematol 2000, 65:285–296.

    Article  PubMed  CAS  Google Scholar 

  15. Lamy T, Devillers A, Bernard M, et al.: Inapparent polycythemia vera—an unrecognized diagnosis. Am J Med 1997, 102:14–20.

    Article  PubMed  CAS  Google Scholar 

  16. Chievitz E, Thiede T: Complications and causes of death in polycythemia vera. Acta Med Scand 1962, 172:513–523.

    Article  PubMed  CAS  Google Scholar 

  17. Turk W: Beitrage zur kenntnis des symptomenbildes polyzythamie mit milztumor und zyanose. Wien Med Wochenschr 1904, 17:153–160, 189–193.

    Google Scholar 

  18. Low J, Popper H: Wien Med Wochenschr 1910, 21:357.

    Google Scholar 

  19. Lesourd L, Pagniez P: Comptes rendus des seances de la Societ’e de Biologie 1910, 68:746.

    Google Scholar 

  20. Fialkow PJ, Gartler SM, Yoshida A: Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci U S A 1967, 58:1468–1471.

    Article  PubMed  CAS  Google Scholar 

  21. Barr RD, Fialkow PJ: Clonal origin of chronic myelocytic leukemia. N Engl J Med 1973, 289:307–309.

    Article  PubMed  CAS  Google Scholar 

  22. Fialkow PJ, Jacobson RJ, Papayannopoulou T: Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977, 63:125–130.

    Article  PubMed  CAS  Google Scholar 

  23. Fialkow PJ, Denman AM, Jacobson RJ, Lowenthal MN: Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. J Clin Invest 1978, 62:815–823.

    Article  PubMed  CAS  Google Scholar 

  24. Jacobson RJ, Salo A, Fialkow PJ: Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978, 51:189–194.

    PubMed  CAS  Google Scholar 

  25. Martin PJ, Najfeld V, Hansen JA, et al.: Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature 1980, 287:49–50.

    Article  PubMed  CAS  Google Scholar 

  26. Fialkow PJ, Faguet GB, Jacobson RJ, et al.: Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981, 58:916–919.

    PubMed  CAS  Google Scholar 

  27. Wasserman LR: The treatment of polycythemia. A panel discussion. Blood 1968, 32:483–487.

    PubMed  CAS  Google Scholar 

  28. Murphy S: Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999,36(1Suppl 2):9–13.

    PubMed  CAS  Google Scholar 

  29. Pearson TC: Diagnosis and classification of erythrocytoses and thrombocytoses. Baillieres Clin Haematol 1998, 11:695–720.

    Article  PubMed  CAS  Google Scholar 

  30. Michiels JJ, Juvonen E: Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost 1997, 23:339–347.

    Article  PubMed  CAS  Google Scholar 

  31. Osler W: Chronic cyanosis, with polycythemia and enlarged spleen: a new clinical entity. Am J Med Sci 1903, 126:187–201.

    Article  Google Scholar 

  32. Osler W: Erythremia (polycythemia with cyanosis, Maladie de Vaquez). Lancet 1908, 1:143–146.

    Google Scholar 

  33. Vaquez MH: Sur une forme speciale de cyanose s’accompagnant d’hyperglobulie excessive et persistante (On a special form of cyanosis accompanied by excessive and persistent erythrocytosis). CR Soc Biol (Paris) 1892, 44:384–388.

    Google Scholar 

  34. Gregersen MI, Rawson RA: Blood volume. Physiol Rev 1959, 39:307–342.

    PubMed  CAS  Google Scholar 

  35. Wright RR, Tono M, Pollycove M: Blood volume. Semin Nucl Med 1975, 5:63–78.

    Article  PubMed  CAS  Google Scholar 

  36. Pearson TC, Guthrie DL, Simpson J, et al.: Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995, 89:748–756.

    Article  PubMed  CAS  Google Scholar 

  37. Hlad CJJr, Tanz R: An analysis of technical errors in radioalbumin blood volume methods and presentation of a modified method. J Lab Clin Med 1958, 52:289–298.

    PubMed  CAS  Google Scholar 

  38. Standard techniques for the measurement of red-cell and plasma volume. A report by the International Committee for Standardization in Hematology (ICSH): Panel on Diagnostic Applications of Radioisotopes in Haematology. Br J Haematol 1973, 25:801–814.

  39. Hinghofer-Szalkay H, Greenleaf JE: Continuous monitoring of blood volume changes in humans. J Appl Physiol 1987, 63:1003–1007.

    PubMed  CAS  Google Scholar 

  40. Balga I, Solenthaler M, Furlan M: Should whole-body red cell mass be measured or calculated? Blood Cells Mol Dis 2000, 26:25–31.

    Article  PubMed  CAS  Google Scholar 

  41. Fairbanks VF: Commentary: should whole-body red cell mass be measured or calculated? Blood Cells Mol Dis 2000, 26:32–36.

    Article  PubMed  Google Scholar 

  42. Ebert RV, Stead EA: Demonstration that the cell/plasma ratio of blood contained in the minute vessels is lower than that of venous blood. J Clin Invest 1941, 20:317.

    PubMed  CAS  Google Scholar 

  43. Reeve EB, Veall N: A simplified method for the determination of circulating red cell volume with radioactive phosphorus. J Physiol 1949, 108:12.

    PubMed  CAS  Google Scholar 

  44. Fairbanks VF, Tauxe WN: Plasma and erythrocyte volumes in obesity, polycythemia, and related conditions. In Compartments, Pools and Spaces in Medical Physiology. Oak Ridge, TN: USAEC Division of Technical Information; 1967:283–298.

    Google Scholar 

  45. Barosi G, Baraldi A, Bellomo G, et.al.: Increased whole body hematocrit: venous hematocrit ratio in diabetes mellitus, evidence of microcirculatory hemoconcentration. Acta Diabetol Lat 1984, 21:257–262.

    Article  PubMed  CAS  Google Scholar 

  46. Costill DL, Saltin B: Changes in the ratio of venous to body hematocrit following dehydration. J Appl Physiol 1974, 36:608–610.

    PubMed  CAS  Google Scholar 

  47. Cocking JB, Wilson E: The whole body-venous haematocrit ratio in chronic non-specific obstructive lung disease. Scand J Haematol 1972, 9:433–436.

    Article  PubMed  CAS  Google Scholar 

  48. Loria A, Sanchez-Medal L, Kauffer N, Quintanar E:Relationship between body hematocrit and venous hematocrit in normal, splenomegalic, and anemic states. J Lab Clin Med 1962, 60:396–408.

    PubMed  CAS  Google Scholar 

  49. Fudenberg H, Baldini M, Mahoney JP, Dameshek W:The body hematocrit/venous hematocrit ratio and the "splenic reservoir." Blood 1961, 17:71–82.

    PubMed  CAS  Google Scholar 

  50. Hope A, Verel D: Further observations on the distribution of red cells and plasma in disease; the low body haematocrit: venous haematocrit ratio. Clin Sci (Lond) 1955, 14:501–507.

    CAS  Google Scholar 

  51. Chaplin H Jr, Mollison PL, Vetter H: The body/venous hematocrit ratio: its constancy over a wide hematocrit range. J Clin Invest 1953, 32:1309–1316.

    PubMed  Google Scholar 

  52. Leslie WD, Dupont JO, Peterdy AE: Effect of obesity on red cell mass results. J Nucl Med 1999, 40:422–428.

    PubMed  CAS  Google Scholar 

  53. Calverley PM, Leggett RJ, McElderry L, Flenley DC: Cigarette smoking and secondary polycythemia in hypoxic cor pulmonale. Am Rev Respir Dis 1982, 125:507–510.

    PubMed  CAS  Google Scholar 

  54. Shih LY, Lee CT, Ou YC: Prediction of clinical course in patients with idiopathic erythrocytosis by endogenous erythroid colony assay but not by serum erythropoietin levels. Exp Hematol 1997, 25:288–292.

    PubMed  CAS  Google Scholar 

  55. Sirhan S, Fairbanks VF, Tefferi A: Red cell mass and plasma volume measurements in polycythemia. Cancer 2005, 104:213–215. The only systematic study that has evaluated the diagnostic accuracy of red cell mass measurement in polycythemia vera.

    Article  PubMed  Google Scholar 

  56. Tefferi A, Lasho TL, Schwager SM, et al.: The clinical phenotype of wild-type, heterozygous, and homozygous JAK2(V617F) in polycythemia vera. Cancer 2005 [Epub ahead of print].

  57. Messinezy M, Westwood NB, El-Hemaidi I, et al.: Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. Br J Haematol 2002, 117:47–53.

    Article  PubMed  CAS  Google Scholar 

  58. Mossuz P, Girodon F, Donnard M, et al.: Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004, 89:1194–1198. An excellent study that looks into the practical value of measuring serum erythropoietin level for the diagnosis of polycythemia vera.

    PubMed  CAS  Google Scholar 

  59. Thiele J, Kvasnicka HM, Muehlhausen K, et al.: Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients. Pathol Res Pract 2001, 197:77–84.

    Article  PubMed  CAS  Google Scholar 

  60. Thiele J, Kvasnicka HM, Zankovich R, Diehl V: The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica 2001, 86:368–374.

    PubMed  CAS  Google Scholar 

  61. Rege-Cambrin G, Mecucci C, Tricot G, et al.: A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet 1987, 25:233–245.

    Article  PubMed  CAS  Google Scholar 

  62. Swolin B, Weinfeld A, Westin J: A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 1988, 72:386–395.

    PubMed  CAS  Google Scholar 

  63. Diez-Martin JL, Graham DL, Petitt RM, Dewald GW:Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc 1991, 66:287–299.

    PubMed  CAS  Google Scholar 

  64. Dobo I, Mossuz P, Campos L, et al.: Comparison of four serum-free, cytokine-free media for analysis of endogenous erythroid colony growth in polycythemia vera and essential thrombocythemia. Hematol J 2001, 2:396–403.

    Article  PubMed  CAS  Google Scholar 

  65. Moliterno AR, Hankins WD, Spivak JL: Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998, 338:572–580.

    Article  PubMed  CAS  Google Scholar 

  66. Tefferi A, Yoon SY, Li CY: Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood 2000, 96:771–772.

    PubMed  CAS  Google Scholar 

  67. Klippel S, Strunck E, Temerinac S, et al.: Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 2003, 102:3569–3574.

    Article  PubMed  CAS  Google Scholar 

  68. Koch CA, Lasho TL, Tefferi A: Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay. Br J Haematol 2004, 127:34–39.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, 200 First Street SW, 55905, Rochester, MN, USA

    Ayalew Tefferi MD

Authors
  1. Ayalew Tefferi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ayalew Tefferi MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tefferi, A. A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2V617F . Curr Hematol Malig Rep 1, 81–86 (2006). https://doi.org/10.1007/s11899-006-0027-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-006-0027-2

Keywords

Search

Navigation